NGLY1 deficiency
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| NGLY1 deficiency | |
|---|---|
| Protein NGLY1 PDB 2ccq | |
| Synonyms | Congenital disorder of deglycosylation |
| Pronounce | |
| Specialty | Medical genetics |
| Symptoms | Developmental delay, movement disorders, liver dysfunction, seizures |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the NGLY1 gene |
| Risks | |
| Diagnosis | Genetic testing, clinical evaluation |
| Differential diagnosis | Other congenital disorders of glycosylation |
| Prevention | None |
| Treatment | Supportive care, physical therapy |
| Medication | |
| Prognosis | Variable |
| Frequency | Very rare |
| Deaths | |
NGLY1 deficiency is a rare genetic disorder caused by mutations in the NGLY1 gene, which encodes the enzyme N-glycanase 1. This enzyme is responsible for the deglycosylation of misfolded glycoproteins in the endoplasmic reticulum-associated degradation (ERAD) pathway. The deficiency leads to a buildup of misfolded glycoproteins, resulting in a variety of clinical symptoms.
Clinical Features[edit]
Patients with NGLY1 deficiency typically present with a range of symptoms, including:
- Developmental delay
- Hypotonia
- Seizures
- Liver dysfunction
- Movement disorders
- Alacrima (reduced tear production)
The severity and combination of symptoms can vary widely among affected individuals.
Genetics[edit]
NGLY1 deficiency is inherited in an autosomal recessive manner. This means that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutation, typically do not show symptoms.
Pathophysiology[edit]
The NGLY1 enzyme plays a crucial role in the ERAD pathway by removing N-linked glycans from misfolded glycoproteins, allowing them to be degraded by the proteasome. In the absence of functional NGLY1, these glycoproteins accumulate, leading to cellular stress and dysfunction.
Diagnosis[edit]
Diagnosis of NGLY1 deficiency is typically confirmed through genetic testing, which identifies mutations in the NGLY1 gene. Biochemical assays may also be used to assess enzyme activity.
Management[edit]
Currently, there is no cure for NGLY1 deficiency. Management focuses on symptomatic treatment and supportive care, which may include:
- Physical therapy for motor skills
- Anticonvulsants for seizure control
- Nutritional support
- Management of liver dysfunction
Research[edit]
Research into NGLY1 deficiency is ongoing, with efforts focused on understanding the molecular mechanisms of the disease and developing potential therapies. Gene therapy and enzyme replacement therapy are areas of active investigation.
